A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
Polymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed, combined...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3202563?pdf=render |
id |
doaj-a98aaea91866421cb44dbb8a305cd9b1 |
---|---|
record_format |
Article |
spelling |
doaj-a98aaea91866421cb44dbb8a305cd9b12020-11-25T00:44:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01610e2661610.1371/journal.pone.0026616A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.Graeme J M CowanAlison M CreaseyKelwalin DhanasarnsombutAlan W ThomasEdmond J RemarqueDavid R CavanaghPolymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed, combined with the relatively conserved Block 1 sequence of MSP-1 and expressed in E.coli. The MSP-1 Hybrid antigen has been produced with high yield by fed-batch fermentation and purified without the aid of affinity tags resulting in a pure and extremely thermostable antigen preparation. MSP-1 hybrid is immunogenic in experimental animals using adjuvants suitable for human use, eliciting antibodies against epitopes from all three Block 2 serotypes. Human serum antibodies from Africans naturally exposed to malaria reacted to the MSP-1 hybrid as strongly as, or better than the same serum reactivities to individual MSP-1 Block 2 antigens, and these antibody responses showed clear associations with reduced incidence of malaria episodes. The MSP-1 hybrid is designed to induce a protective antibody response to the highly polymorphic Block 2 region of MSP-1, enhancing the repertoire of MSP-1 Block 2 antibody responses found among immune and semi-immune individuals in malaria endemic areas. The target population for such a vaccine is young children and vulnerable adults, to accelerate the acquisition of a full range of malaria protective antibodies against this polymorphic parasite antigen.http://europepmc.org/articles/PMC3202563?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Graeme J M Cowan Alison M Creasey Kelwalin Dhanasarnsombut Alan W Thomas Edmond J Remarque David R Cavanagh |
spellingShingle |
Graeme J M Cowan Alison M Creasey Kelwalin Dhanasarnsombut Alan W Thomas Edmond J Remarque David R Cavanagh A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. PLoS ONE |
author_facet |
Graeme J M Cowan Alison M Creasey Kelwalin Dhanasarnsombut Alan W Thomas Edmond J Remarque David R Cavanagh |
author_sort |
Graeme J M Cowan |
title |
A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
title_short |
A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
title_full |
A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
title_fullStr |
A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
title_full_unstemmed |
A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response. |
title_sort |
malaria vaccine based on the polymorphic block 2 region of msp-1 that elicits a broad serotype-spanning immune response. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2011-01-01 |
description |
Polymorphic parasite antigens are known targets of protective immunity to malaria, but this antigenic variation poses challenges to vaccine development. A synthetic MSP-1 Block 2 construct, based on all polymorphic variants found in natural Plasmodium falciparum isolates has been designed, combined with the relatively conserved Block 1 sequence of MSP-1 and expressed in E.coli. The MSP-1 Hybrid antigen has been produced with high yield by fed-batch fermentation and purified without the aid of affinity tags resulting in a pure and extremely thermostable antigen preparation. MSP-1 hybrid is immunogenic in experimental animals using adjuvants suitable for human use, eliciting antibodies against epitopes from all three Block 2 serotypes. Human serum antibodies from Africans naturally exposed to malaria reacted to the MSP-1 hybrid as strongly as, or better than the same serum reactivities to individual MSP-1 Block 2 antigens, and these antibody responses showed clear associations with reduced incidence of malaria episodes. The MSP-1 hybrid is designed to induce a protective antibody response to the highly polymorphic Block 2 region of MSP-1, enhancing the repertoire of MSP-1 Block 2 antibody responses found among immune and semi-immune individuals in malaria endemic areas. The target population for such a vaccine is young children and vulnerable adults, to accelerate the acquisition of a full range of malaria protective antibodies against this polymorphic parasite antigen. |
url |
http://europepmc.org/articles/PMC3202563?pdf=render |
work_keys_str_mv |
AT graemejmcowan amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alisonmcreasey amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT kelwalindhanasarnsombut amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alanwthomas amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT edmondjremarque amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT davidrcavanagh amalariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT graemejmcowan malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alisonmcreasey malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT kelwalindhanasarnsombut malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT alanwthomas malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT edmondjremarque malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse AT davidrcavanagh malariavaccinebasedonthepolymorphicblock2regionofmsp1thatelicitsabroadserotypespanningimmuneresponse |
_version_ |
1725275152872112128 |